Anti-inflammatory treatment with acetylsalicylate or rofecoxib is not neuroprotective in Huntington's disease transgenic mice
about
Mutant huntingtin-impaired degradation of beta-catenin causes neurotoxicity in Huntington's diseaseMouse models of polyglutamine diseases: review and data table. Part IRole of prostaglandins in neuroinflammatory and neurodegenerative diseasesMouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.Does neuroinflammation fan the flame in neurodegenerative diseases?Neuroimmunology of Huntington's Disease: Revisiting Evidence from Human StudiesNonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice.The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies.The role of the immune system in Huntington's disease.A mitochondrial basis for Huntington's disease: therapeutic prospects.Changing paradigm to target microglia in neurodegenerative diseases: from anti-inflammatory strategy to active immunomodulation.Huntington's Disease: Pathogenic Mechanisms and Therapeutic Targets.Human tissue transglutaminase is inhibited by pharmacologic and chemical acetylation.Animal welfare and the refinement of neuroscience research methods--a case study of Huntington's disease models.Promises and pitfalls of immune-based strategies for Huntington's disease.7,8-dihydroxyflavone ameliorates cognitive and motor deficits in a Huntington's disease mouse model through specific activation of the PLCγ1 pathway.
P2860
Q24317702-A6DF3363-9BBE-4BC7-BCBD-420C689FF222Q26853025-DE192B16-8DD7-4B93-B9AA-8B85BFCA73F1Q26863534-1434014B-1B4F-4015-A7A6-17ED1DE70E69Q27005950-AD051324-639A-4C0F-818C-01053424B54BQ27498993-871921E0-1CB4-4A93-865B-AF71B41C9AFEQ28072237-475D697A-B432-4929-B2CF-3A6D9089F53AQ33713689-EA6D9C8D-B7F6-43C6-84CF-CF2BA50BA7ECQ36358871-7D51AF80-45E3-4781-A125-F616B1CCEF3BQ38129870-B34D309D-ABD2-40EA-A26D-0E486BD27EA9Q38174451-63398BC9-84A5-4C34-9585-445D84C6A05FQ38633556-D755E0B8-E71F-448F-8A57-465069D71719Q38663090-77D6CB10-3E5D-455D-885A-8460B0F1F812Q40403566-2FA36A63-EF61-464E-B817-B92A05DB32AFQ45290079-200A0990-725A-4765-96D2-E63ED6FA3F4BQ45305225-D7270116-76AA-455C-9D61-E0AAC605D095Q50206457-D4E11B78-4E7A-4C7C-98E2-A054AE7AC8FC
P2860
Anti-inflammatory treatment with acetylsalicylate or rofecoxib is not neuroprotective in Huntington's disease transgenic mice
description
2004 nî lūn-bûn
@nan
2004 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Anti-inflammatory treatment wi ...... gton's disease transgenic mice
@ast
Anti-inflammatory treatment wi ...... gton's disease transgenic mice
@en
Anti-inflammatory treatment wi ...... gton's disease transgenic mice
@nl
type
label
Anti-inflammatory treatment wi ...... gton's disease transgenic mice
@ast
Anti-inflammatory treatment wi ...... gton's disease transgenic mice
@en
Anti-inflammatory treatment wi ...... gton's disease transgenic mice
@nl
prefLabel
Anti-inflammatory treatment wi ...... gton's disease transgenic mice
@ast
Anti-inflammatory treatment wi ...... gton's disease transgenic mice
@en
Anti-inflammatory treatment wi ...... gton's disease transgenic mice
@nl
P2093
P50
P3181
P1476
Anti-inflammatory treatment wi ...... gton's disease transgenic mice
@en
P2093
Agnes Nanje
Fran Norflus
Geming Shi
Jonathan Fox
Joshua Cohen
Michelle Bejarano
P304
P3181
P356
10.1016/J.NBD.2004.07.011
P407
P577
2004-11-01T00:00:00Z